U.S. Markets open in 4 hrs 39 mins

Celgene Corporation (CELG)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
127.43-0.22 (-0.17%)
At close: 4:00PM EDT

127.88 +0.45 (0.35%)
Pre-Market: 4:00AM EDT

People also watch
GILDBIIBREGNAMGNVRTX

Celgene Corporation

86 Morris Avenue
Summit, NJ 07901
United States
908-673-9000
http://www.celgene.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees7,132

Key Executives

NameTitlePayExercisedAge
Mr. Robert J. Hugin MBAExec. Chairman8.04M1.74M62
Mr. Mark J. AllesCEO & Director4.77M1.6M58
Mr. Scott Andrew SmithPres & COO2.01MN/A55
Mr. Peter N. Kellogg BSE, MBACFO, Chief Accounting Officer & Exec. VP3.58MN/A61
Dr. Thomas O. Daniel M.D.Chairman of Celgene ResearchN/AN/A63
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

Corporate Governance

Celgene Corporation’s ISS Governance QualityScore as of August 1, 2017 is 4. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 2; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.